Working... Menu

Hepcidin Levels in Preterm Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01539356
Recruitment Status : Completed
First Posted : February 27, 2012
Last Update Posted : March 16, 2016
Information provided by (Responsible Party):
Meir Medical Center

Brief Summary:
A recently isolated peptide hormone, hepcidin, is thought to be the principal regulator of iron homeostasis. Hepcidin acts by limiting intestinal iron absorption and promoting iron retention in reticuloendothelial cells. The aims of this study were to determine serum hepcidin levels in preterm infants who receive blood transfusion and preterm infants having sepsis, in order to assess possible relationships between hepcidin and serum iron, serum ferritin,in iron load situations.

Condition or disease
Preterm Infants Anemia of Prematurity Neonatal Sepsis

Layout table for study information
Study Type : Observational
Actual Enrollment : 62 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Hepcidin Levels in Preterm Infants Receiving Blood Transfusion and During Sepsis.
Study Start Date : March 2012
Actual Primary Completion Date : February 2013
Actual Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

preterm infants

preterm infants receiving blood transfusion

preterm infants with neonatal sepsis.

Primary Outcome Measures :
  1. Increase in Hepcidin levels by 30% [ Time Frame: within 24-72 h ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   24 Weeks to 37 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Preterm < 38 weeks gestation Need of blood transfusion according to local Protocol. or signs and symptoms of sepsis

Inclusion Criteria:

  • Preterm < 38 weeks gestation
  • Need of blood test for anemia or suspected sepsis

Exclusion Criteria:

  • Major congenital anomalies
  • Birth Asphyxia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01539356

Layout table for location information
Neonatal Intensive Care Unit
Kfar-Saba, Israel, 44281
Sponsors and Collaborators
Meir Medical Center

Layout table for additonal information
Responsible Party: Meir Medical Center Identifier: NCT01539356     History of Changes
Other Study ID Numbers: 0154-11-MMC
First Posted: February 27, 2012    Key Record Dates
Last Update Posted: March 16, 2016
Last Verified: November 2012

Keywords provided by Meir Medical Center:
Preterm Infants

Additional relevant MeSH terms:
Layout table for MeSH terms
Premature Birth
Neonatal Sepsis
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Systemic Inflammatory Response Syndrome
Pathologic Processes
Infant, Newborn, Diseases
Anti-Infective Agents